IRCT20221221056889N1招募中未知
Comparison the effects of Empaglifluzin-linagliptin and Dapaglifluzin-linagliptin on HbA1c ? LDL and Albuminuria in patients with T2DM
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30 years 至 75 years（—）
- 性别
- All
入选标准
- •Having type 2 diabetes
- •Hb A1c above 7 and below 11
- •No acute hospitalization conditions
- •Age between 30 and 75 years
- •Patients with albuminuria
- •Not taking the drug beforehand
排除标准
- •Acute hospitalization conditions
- •Pre-medication
研究者
相似试验
尚未招募
3 期
Comparison the Effect of Empaglifluzin and Linagliptin on the Albuminuria of diabetic patientsIRCT20200722048176N1Arak University of Medical Sciences60
招募中
2 期
Effect of Linagliptin and Empagliflozine on diabetesIRCT20221016056201N1Arak University of Medical Sciences55
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
尚未招募
2 期
The effect of Empagliflozin on nonalcoholic fatty liver disease in non-diabetic patientson alcoholic fatty liver disease.Nonalcoholic steatohepatitis [NASH]K75.81IRCT20190122042450N1Iran University of Medical Sciences100
招募中
2 期
The cardiac effect of pioglitazone and empagliflozin among diabetic patients with NAFLDCondition 1: Nonalcoholic fatty liver disease. Condition 2: Type 2 Diabetes. Condition 3: Cardiomyopathy.Nonalcoholic steatohepatitis (NASH)Type 2 diabetesK75.81CardiomyopathyIRCT20190122042450N5Iran University of Medical Sciences70